Shopping Cart 0
Cart Subtotal
USD 0

Onxeo SA (ONXEO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Onxeo SA (Onxeo) is a manufacturer of drugs that offers development, and registration of orphan oncology drugs for the treatment of cancer. The company provides pipeline products such as livatag, belchop, beleodaq, amep, asidna and validive, among others. It offers drugs for the treatment of liver cancer, and treatment and prevention of radio chemotherapy, head cancer and neck cancer, among others. Onxeo's livatag is a nanoparticle formulation of doxorubicin, which is developed for the treatment of primary liver cancer. The company provides preclinical and clinical development, regulatory affairs, and other services. It markets its products through its distribution network. Onxeo is headquartered in Paris, France.

Onxeo SA (ONXEO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Onxeo SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Onxeo SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Onxeo SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Onxeo SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Onxeo SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Onxeo SA, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Onxeo Enters into Research Agreement with Royal College of Surgeons in Ireland 11

Onxeo Enters into Agreement with Centro de Investigacion Medica Aplicada 12

Onxeo Enters into Agreement with Croix-Rousse Hospital and Centre de Recherche en Cancerologie 13

Onxeo Enters into Agreement with Synovo 14

DARA BioSciences Enters into Commercialization Agreement with Onxeo 15

Licensing Agreements 16

SWK Holdings Receives Beleodaq Royalty Rights from Onxeo 16

Monopar Therapeutics Enters into Licensing Agreement with Onxeo 17

Pint Pharma Enters into Licensing Agreement with Onxeo for Beleodaq 18

Onxeo Enters into Licensing Agreement with Bruno Farmaceutici 19

Equity Offering 20

Onxeo to Raise USD6.3 Million in Equity Financing 20

Onxeo Raises USD16.7 Million in Private Placement of Shares 22

Onxeo Raises USD14 Million in Private Placement of Shares 23

Onxeo to Raise USD1 Million in Private Placement of Shares 24

Onxeo Raises USD51 Million in Rights Offering 25

Asset Transactions 27

Vectans Pharma to Acquire Sitavig and Loramyc from Onxeo 27

Acquisition 28

Onxeo Acquires DNA Therapeutics 28

Onxeo SA-Key Competitors 29

Onxeo SA-Key Employees 30

Onxeo SA-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Joint Venture 31

Recent Developments 33

Financial Announcements 33

Jul 27, 2018: Onxeo Reports Half-Year 2018 Financial Results and Provides Business Outlook 33

May 16, 2018: Onxeo Provides Business Update and Reports First Quarter 2018 Financial Information 36

Mar 29, 2018: Onxeo Reports Full-Year 2017 Financial Results and Provides Business Update 37

Oct 26, 2017: Onxeo Provides Strategy Update and Reports 2017 Third Quarter Financial Information 40

Jul 28, 2017: Onxeo Reports First-Half 2017 Results and Business Update 41

Apr 26, 2017: Onxeo: Q1 2017 financial information and business update 43

Mar 07, 2017: Onxeo: Full-year 2016 Results and Outlook for 2017 44

Corporate Communications 46

Mar 01, 2017: Onxeo Appoints Seasoned Executives to Accelerate Preclinical and Clinical Development 46

Mar 01, 2017: Onxeo announces two new executive appointments 47

Legal and Regulatory 48

Jan 23, 2018: Onxeo Announces Update On Litigation with SpeBio/SpePharm 48

Product News 49

Oct 02, 2017: Onxeo Introduces platON, a Proprietary Chemistry Platform of Decoy Oligonucleotides 49

04/24/2017: Clinigen and Onxeo initiate Managed Access programme for belinostat in Europe for patients with peripheral T-cell lymphoma 50

03/31/2017: Spectrum Pharmaceuticals Highlights Two Abstracts on BELEODAQ (belinostat) for injection at the American Association for Cancer Research (AACR) Annual Meeting in Washington 51

03/21/2017: Onxeo to Present Data on Key Orphan Oncology Asset Beleodaq at AACR Annual Meeting 52

Other Significant Developments 53

Mar 14, 2018: Onxeo Provides Financial Update 53

Appendix 54

Methodology 54

About GlobalData 54

Contact Us 54

Disclaimer 54


List Of Figure

List of Figures

Onxeo SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Onxeo SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Onxeo SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Onxeo SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Onxeo SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Onxeo SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Onxeo SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Onxeo SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Onxeo SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Onxeo SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Onxeo SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Onxeo SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Onxeo SA, Deals By Therapy Area, 2012 to YTD 2018 9

Onxeo SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Onxeo Enters into Research Agreement with Royal College of Surgeons in Ireland 11

Onxeo Enters into Agreement with Centro de Investigacion Medica Aplicada 12

Onxeo Enters into Agreement with Croix-Rousse Hospital and Centre de Recherche en Cancerologie 13

Onxeo Enters into Agreement with Synovo 14

DARA BioSciences Enters into Commercialization Agreement with Onxeo 15

SWK Holdings Receives Beleodaq Royalty Rights from Onxeo 16

Monopar Therapeutics Enters into Licensing Agreement with Onxeo 17

Pint Pharma Enters into Licensing Agreement with Onxeo for Beleodaq 18

Onxeo Enters into Licensing Agreement with Bruno Farmaceutici 19

Onxeo to Raise USD6.3 Million in Equity Financing 20

Onxeo Raises USD16.7 Million in Private Placement of Shares 22

Onxeo Raises USD14 Million in Private Placement of Shares 23

Onxeo to Raise USD1 Million in Private Placement of Shares 24

Onxeo Raises USD51 Million in Rights Offering 25

Vectans Pharma to Acquire Sitavig and Loramyc from Onxeo 27

Onxeo Acquires DNA Therapeutics 28

Onxeo SA, Key Competitors 29

Onxeo SA, Key Employees 30

Onxeo SA, Subsidiaries 31

Onxeo SA, Joint Venture 31

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Onxeo SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.